GB201010588D0 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
GB201010588D0
GB201010588D0 GBGB1010588.0A GB201010588A GB201010588D0 GB 201010588 D0 GB201010588 D0 GB 201010588D0 GB 201010588 A GB201010588 A GB 201010588A GB 201010588 D0 GB201010588 D0 GB 201010588D0
Authority
GB
United Kingdom
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1010588.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Priority to GBGB1010588.0A priority Critical patent/GB201010588D0/en
Publication of GB201010588D0 publication Critical patent/GB201010588D0/en
Priority to PCT/GB2011/051180 priority patent/WO2011161457A1/en
Priority to GB1301168.9A priority patent/GB2497216B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
GBGB1010588.0A 2010-06-23 2010-06-23 Cancer treatment Ceased GB201010588D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1010588.0A GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment
PCT/GB2011/051180 WO2011161457A1 (en) 2010-06-23 2011-06-23 Cancer treatment
GB1301168.9A GB2497216B (en) 2010-06-23 2011-06-23 A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1010588.0A GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment

Publications (1)

Publication Number Publication Date
GB201010588D0 true GB201010588D0 (en) 2010-08-11

Family

ID=42582889

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1010588.0A Ceased GB201010588D0 (en) 2010-06-23 2010-06-23 Cancer treatment
GB1301168.9A Expired - Fee Related GB2497216B (en) 2010-06-23 2011-06-23 A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1301168.9A Expired - Fee Related GB2497216B (en) 2010-06-23 2011-06-23 A method of increasing the sensitivity of a cell to DNA double strand damage in vitro and inhibitors of H1x function

Country Status (2)

Country Link
GB (2) GB201010588D0 (en)
WO (1) WO2011161457A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248233A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California Delivery system using mab 3e10 and mutants and/or functional fragments thereof

Also Published As

Publication number Publication date
GB201301168D0 (en) 2013-03-06
WO2011161457A1 (en) 2011-12-29
GB2497216A (en) 2013-06-05
GB2497216B (en) 2015-11-11

Similar Documents

Publication Publication Date Title
IL267242B (en) Cancer treatment
HK1175476A1 (en) Cancer treatment
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
PL2652193T3 (en) Treatment
EP2611496A4 (en) Treatment methods
IL222481A0 (en) Combination therapy
SG10201508495VA (en) Combination treatment of cancer
EP2552323A4 (en) Combination therapy
GB201016139D0 (en) Cancer phosholipidome
IL222958A0 (en) Cancer treatment
EP2521569A4 (en) Combined treatment utilizing vb-201
EP2635286A4 (en) Methods for treating cancer
EP2603222A4 (en) Combinatory cancer treatment
HK1210023A1 (en) Cancer treatment
GB201013573D0 (en) Treatment
EP2585115A4 (en) Cancer therapy
GB201005394D0 (en) Therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
GB201014097D0 (en) Treatment
EP2629766A4 (en) Combination therapy
GB201301168D0 (en) Cancer treatment
GB201020513D0 (en) Cancer therapy
GB201017354D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)